An osmium-peroxo complex for photoactive therapy of hypoxic tumors

Nat Commun. 2022 Apr 26;13(1):2245. doi: 10.1038/s41467-022-29969-z.

Abstract

The limited therapeutic effect on hypoxic and refractory solid tumors has hindered the practical application of photodynamic therapy. Herein, we report our investigation of an osmium-peroxo complex (Os2), which is inactive in the dark, but can release a peroxo ligand O2•- upon light irradiation even in the absence of oxygen, and is transformed into a cytotoxic osmium complex (Os1). Os1 is cytotoxic in the presence or absence of irradiation in hypoxic tumors, behaving as a chemotherapeutic drug. At the same time, the light-activated Os2 induces photocatalytic oxidation of endogenous 1,4-dihydronicotinamide adenine dinucleotide in living cancer cells, leading to ferroptosis, which is mediated by glutathione degradation, lipid peroxide accumulation and down-regulation of glutathione peroxidase 4. In vivo studies have confirmed that the Os2 can effectively inhibit the growth of solid hypoxic tumors in mice. A promising strategy is proposed for the treatment of hypoxic tumors with metal-based drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Hypoxia / metabolism
  • Mice
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Osmium
  • Oxygen
  • Photochemotherapy*

Substances

  • Antineoplastic Agents
  • Osmium
  • Oxygen

Associated data

  • figshare/10.6084/m9.figshare.19333802